打破癌症代码:一种新的DNA小圈,在卵巢癌细胞SKOV3中禁用STAT3
Adina-Gabriela Vasilescu1, Andrei-Mihai Vasilescu1, Livia Elena Sima2
1Department of Enzymology, Institute of Biochemistry of the Romanian Academy, Bucharest, Romania.
一种针对信号转换器和转录3激活器 (STAT3) 的新型DNA小环抑制剂有效降低了卵巢癌细胞的活力和增殖. 这种STAT3抑制剂通过降低关键瘤基因的调节,显示出治疗卵巢癌的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因治疗 基因治疗
背景情况:
- 卵巢癌是一个重大的全球健康挑战,死亡率高,通常与晚诊症和有限的治疗疗效有关.
- 信号转换器和转录3激活器 (STAT3) 的持续激活是驱动瘤生长,转移,免疫逃避和卵巢癌中化学抵抗的关键内在机制.
- 由STAT3培养的攻击性表型有助于治疗失败和患者生存率低下,这强调了针对性STAT3治疗的必要性.
研究的目的:
- 开发和评估一种新型的双链DNA小圈 (mcDNA) 抑制剂,该抑制剂旨在作为STAT3的诱,从而防止其与向基因促进体结合.
- 评估抗STAT3mcDNA抑制剂在降低卵巢癌细胞活力,诱导亡和亡以及调节STAT3调节基因表达中的有效性.
主要方法:
- 该研究利用SKOV3卵巢癌细胞系进行体外实验.
- 使用MTS试验评估了细胞活力.
- 通过流式细胞计量评估了亡和亡效应,并使用RT-qPCR和西方斑点分析分析了STAT3调节基因的表达.
主要成果:
- 抗STAT3mcDNA抑制剂在低纳米分子度下显著降低SKOV3细胞活力,以剂量依赖的方式.
- 用抗STAT3mcDNA治疗诱导治疗细胞的亡和亡,并降低细胞增殖.
- 该抑制剂有效降低了STAT3依赖的抗亡基因,特别是MCL1和PIM1.
结论:
- 开发的抗STAT3mcDNA显示出作为卵巢癌细胞中STAT3的有效和特异性抑制剂的巨大潜力.
- 这些发现支持在卵巢癌模型中进一步验证抗STAT3mcDNA,包括体内研究.
- 治疗策略也可能适用于其他恶性瘤,其中STAT3发挥关键的瘤作用.
更多相关视频
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
